Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Science Immunology|April 7, 2023
Computational prediction of MHC anchor locations guides neoantigen identification and prioritizationHuiming Xia, Joshua McMichael, Michelle Becker-Hapak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2021
Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin LymphomaJennifer A Foltz, Brian T Hess, Veronika Bachanova, et al.
Cancer Discovery|August 23, 2020
Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for LeukemiaMelissa M Berrien-Elliott, Amanda F Cashen, Celia C Cubitt, et al.
Science Immunology|June 28, 2024
Cytokines drive the formation of memory-like NK cell subsets via epigenetic rewiring and transcriptional regulationJennifer A Foltz, Jennifer Tran, Pamela Wong, et al.
The Journal of Clinical Investigation|June 6, 2023
T-BET and EOMES sustain mature human NK cell identity and antitumor functionPamela Wong, Jennifer A Foltz, Lily Chang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 9, 2023
Memory-like Differentiation, Tumor-Targeting mAbs, and Chimeric Antigen Receptors Enhance Natural Killer Cell Responses to Head and Neck CancerMiriam T Jacobs, Pamela Wong, Alice Y Zhou, et al.
Blood Advances|May 7, 2024
Neoantigen landscape supports feasibility of personalized cancer vaccine for follicular lymphomaCody A Ramirez, Michelle Becker-Hapak, Kartik Singhal, et al.
Science Translational Medicine|February 23, 2022
Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemiaMelissa M Berrien-Elliott, Jennifer A Foltz, David A Russler-Germain, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 2021
Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood-Derived NK Cells Facilitates CAR-like Responses Against CD30+ MalignanciesLucila N Kerbauy, Nancy D Marin, Mecit Kaplan, et al.
Pageof 5